Derek Lowe doesn't think RNAi will ever be useful in drug therapies, mainly because "nucleic acid-based therapies are just nightmarish to administer," he says. And he's not the only one. In a post at In the Pipeline, Lowe links to a recent CNBC story that details Leerink Swann's coverage of Alnylam.